The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Clinical and economic burden of adverse drug reactions
Open accessAbstract
Adverse drug reactions (ADRs) are unwanted drug effects that have considerable economic as well as clinical costs as they often lead to hospital admission, prolongation of hospital stay and emergency department visits. Randomized controlled trials (RCTs) are the main premarketing methods used to detect and quantify ADRs but these have several limitations, such as limited study sample size and limited heterogeneity due to the exclusion of the frailest patients. In addition, ADRs due to inappropriate medication use occur often in the real world of clinical practice but not in RCTs. Postmarketing drug safety monitoring through pharmacovigilance activities, including mining of spontaneous reporting and carrying out observational prospective cohort or retrospective database studies, allow longer follow-up periods of patients with a much wider range of characteristics, providing valuable means for ADR detection, quantification and where possible reduction, reducing healthcare costs in the process. Overall, pharmacovigilance is aimed at identifying drug safety signals as early as possible, thus minimizing potential clinical and economic consequences of ADRs. The goal of this review is to explore the epidemiology and the costs of ADRs in routine care.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients
Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A. K., Walley, T. J., Farrar, K., Park, B. K., & Breckenridge, A. M. (2004) · BMJ · doi:10.1136/bmj.329.7456.15 · Cited by 3,230
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
Rothwell, P. M. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17670-8 · Cited by 2,544
Bates, D. W. (1997) · JAMA · doi:10.1001/jama.277.4.307 · Cited by 1,674
Why we need observational studies to evaluate the effectiveness of health care
Black, N. (1996) · BMJ · doi:10.1136/bmj.312.7040.1215 · Cited by 1,598
Better Reporting of Harms in Randomized Trials: An Extension of the CONSORT Statement
Ioannidis, J. P. A., Evans, S. J. W., Gøtzsche, P. C., O'Neill, R. T., Altman, D. G., Schulz, K., Moher, D., & for the CONSORT Group* (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-141-10-200411160-00009 · Cited by 1,593
Classen, D. C. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540280039031 · Cited by 1,134
Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
Landefeld, C. S., & Beyth, R. J. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90285-w · Cited by 893
Adverse Drug Reactions in Hospital In-Patients: A Prospective Analysis of 3695 Patient-Episodes
Davies, E. C., Green, C. F., Taylor, S., Williamson, P. R., Mottram, D. R., & Pirmohamed, M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004439 · Cited by 692
Grey zones of clinical practice: some limits to evidence-based medicine
Naylor, C. D. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92969-x · Cited by 663
Problems in the “Evidence” of “Evidence-Based Medicine”
Feinstein, A. R., & Horwitz, R. I. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00244-1 · Cited by 653 · cited 1×
“[6,7,8,9,10,11,12,13] The selection of patients for RCTs may also not be representative of patients who will receive the treatment and who may be more vulnerable to ADRs.”
Which drugs cause preventable admissions to hospital? A systematic review
Howard, R. L., Avery, A. J., Slavenburg, S., Royal, S., Pipe, G., Lucassen, P., & Pirmohamed, M. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02698.x · Cited by 625
Cullen, D. J., Sweitzer, B. J., Bates, D. W., Burdick, E., Edmondson, A., & Leape, L. L. (1997) · Critical Care Medicine · doi:10.1097/00003246-199708000-00014 · Cited by 611
Medication Use Leading to Emergency Department Visits for Adverse Drug Events in Older Adults
Budnitz, D. S., Shehab, N., Kegler, S. R., & Richards, C. L. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00006 · Cited by 607
Impicciatore, P., Choonara, I., Clarkson, A., Provasi, D., Pandolfini, C., & Bonati, M. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01407.x · Cited by 513
Adverse drug reactions in elderly patients
Routledge, P. A., O'Mahony, M. S., & Woodhouse, K. W. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01875.x · Cited by 476
Inappropriate Medication is a Major Cause of Adverse Drug Reactions in Elderly Patients
LINDLEY, C. M., TULLY, M. P., PARAMSOTHY, V., & TALLIS, R. C. (1992) · Age and Ageing · doi:10.1093/ageing/21.4.294 · Cited by 389
Is inappropriate medication use a major cause of adverse drug reactions in the elderly?
Laroche, M., Charmes, J., Nouaille, Y., Picard, N., & Merle, L. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2006.02831.x · Cited by 317
Reporting of Safety Results in Published Reports of Randomized Controlled Trials
(2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.306 · Cited by 287
Randomized Clinical Trials and Observational Studies
Hannan, E. L. (2008) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2008.01.008 · Cited by 283
The causes and effects of socio-demographic exclusions from clinical trials
Bartlett, C., Doyal, L., Ebrahim, S., Davey, P., Bachmann, M., Egger, M., & Dieppe, P. (2005) · Health Technology Assessment · doi:10.3310/hta9380 · Cited by 250
The Epidemiology of Serious Adverse Drug Reactions Among the Elderly
Atkin, P. A., Veitch, P. C., Veitch, E. M., & Ogle, S. J. (1999) · Drugs & Aging · doi:10.2165/00002512-199914020-00005 · Cited by 203
Olsen, S., Neale, G., Schwab, K., Psaila, B., Patel, T. A., Chapman, E. J., & Vincent, C. A. (2007) · BMJ Quality & Safety · doi:10.1136/qshc.2005.017616 · Cited by 200
Selection of Patients with Acute Myocardial Infarction for Thrombolytic Therapy
Muller, D. W. M., & Topol, E. J. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-113-12-949 · Cited by 197
Counting the Costs of Drug-Related Adverse Events
White, T. J., Arakelian, A., & Rho, J. P. (1999) · PharmacoEconomics · doi:10.2165/00019053-199915050-00003 · Cited by 197
Charlton, B. G., & Miles, A. (1998) · QJM · doi:10.1093/qjmed/91.5.371 · Cited by 186
Trifirò, G., & Spina, E. (2011) · Current Drug Metabolism · doi:10.2174/138920011796504473 · Cited by 161
Self-citationDifferences between clinical trials and postmarketing use
Martin, K., Bégaud, B., Latry, P., Miremont‐Salamé, G., Fourrier, A., & Moore, N. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01953.x · Cited by 157 · cited 12×
“[6-13] The selection of patients for RCTs may also not be representative of patients who will receive the treatment and who may be more vulnerable to ADRs.”
InfluentialObservational studies: going beyond the boundaries of randomized controlled trials
Yang, W., Zilov, A. V., Soewondo, P., Bech, O. M., Sekkal, F., & Home, P. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(10)70002-4 · Cited by 156
The Costs Associated With Adverse Drug Events Among Older Adults in the Ambulatory Setting
Field, T. S., Gilman, B. H., Subramanian, S., Fuller, J. C., Bates, D. W., & Gurwitz, J. H. (2005) · Medical Care · doi:10.1097/01.mlr.0000185690.10336.70 · Cited by 151
Adverse Events Related to Drugs and Drug Withdrawal in Nursing Home Residents
Cerety, M. B., Cornell, J. E., Dt, P., & Eimer, M. (1993) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1993.tb06483.x · Cited by 125
Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation
Antani, M. R., Beyth, R. J., Covinsky, K. E., Anderson, P. A., Miller, D. G., Cebul, R. D., Quinn, L., & Landefeld, C. S. (1996) · Journal of General Internal Medicine · doi:10.1007/bf02598984 · Cited by 123
Kalisch, L. M., Caughey, G. E., Roughead, E. E., & Gilbert, A. L. (2011) · Australian Prescriber · doi:10.18773/austprescr.2011.084 · Cited by 123
Evidence-based and Evidence-biased Medicine
EVANS, J. G. (1995) · Age and Ageing · doi:10.1093/ageing/24.6.461 · Cited by 112
Šeruga, B., Sterling, L., Wang, L. E., & Tannock, I. F. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.9624 · Cited by 112
Walker, M. C., & Sander, J. W. A. S. (1997) · Neurology · doi:10.1212/wnl.49.2.333 · Cited by 97
Reporting of safety data from randomised trials
Ioannidis, J. P. A., & Contopoulos‐Ioannidis, D. G. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79825-1 · Cited by 97
Study of information submitted by drug companies to licensing authorities.
Hemminki, E. (1980) · BMJ · doi:10.1136/bmj.280.6217.833 · Cited by 96
Probable Adverse Drug Reactions in a Rural Geriatric Nursing Home Population: A Four‐Year Study
Cooper, J. W. (1996) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1996.tb02439.x · Cited by 93
Evidence based medicine: concerns of a clinical neurologist
Caplan, L. R. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.5.569 · Cited by 92
Challenging issues in randomised controlled trials
Nichol, A., Bailey, M., & Cooper, D. J. (2010) · Injury · doi:10.1016/j.injury.2010.03.033 · Cited by 87
Adverse drug events in emergency department population: a prospective Italian study
Trifirò, G., Calogero, G., Menniti‐Ippolito, F., Cosentino, M., Giuliani, R., Conforti, A., Venegoni, M., Mazzaglia, G., & Caputi, A. P. (2005) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1074 · Cited by 71
Self-citationBlack, D. A. K. (1998) · PubMed Central · Cited by 62
Randomized controlled trials in schizophrenia: a critical perspective on the literature
Gilbody, S. M., Wahlbeck, K., & Adams, C. E. (2002) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2002.00242.x · Cited by 55
Reporting the study populations of clinical trials
Shapiro, S. H., Weijer, C., & Freedman, B. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00227-4 · Cited by 51
Distinguishing Hazards and Harms, Adverse Drug Effects and Adverse Drug Reactions
Aronson, J. K. (2013) · Drug Safety · doi:10.1007/s40264-013-0019-9 · Cited by 42
The Safety of New Medicines: The Importance of Asking the Right Questions
Wood, A. J. J. (1999) · JAMA · doi:10.1001/jama.281.18.1753 · Cited by 34
Steiner, T. J., & Rose, F. C. (1986) · Neuroepidemiology · doi:10.1159/000110823 · Cited by 25
Henderson, R. A., Raskino, C., & Hampton, J. R. (1995) · QJM · doi:10.1093/oxfordjournals.qjmed.a069042 · Cited by 23
Hampton, J. R. (2002) · Statistics in Medicine · doi:10.1002/sim.1284 · Cited by 22
Oswald, N., & Bateman, H. (1999) · Family Practice · doi:10.1093/fampra/16.4.414 · Cited by 20
On evidence, embellishment and efficacy
Morgan, W. K. (1997) · Journal of Evaluation in Clinical Practice · doi:10.1046/j.1365-2753.1997.00077.x · Cited by 13
What do clinical trials tell us about treating patients?
Weiner, W. J. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70776-x · Cited by 13
Generalisability of clinical trials in otitis media with effusion
Rovers, M. M., Zielhuis, G. A., Bennett, K., & Haggard, M. P. (2001) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/s0165-5876(01)00504-3 · Cited by 11
Kojima, T., Akishita, M., Kameyama, Y. U., Yamaguchi, K., Yamamoto, H., Eto, M., & Ouchi, Y. (2012) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2012.03975.x · Cited by 11
Design of clinical antiepileptic drug trials
Binnie, C. D. (1995) · Seizure · doi:10.1016/s1059-1311(05)80059-7 · Cited by 9
Randomized, Controlled Trials: Gold or bronze?
Cheng, H. (2006) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2006.09.003 · Cited by 6
Cited by
The growing role of precision and personalized medicine for cancer treatment
Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berrios, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., et al. (2018) · TECHNOLOGY · doi:10.1142/s2339547818300020 · Cited by 698
Pharmacogenomics of GPCR Drug Targets
Hauser, A. S., Chavali, S., Masuho, I., Jahn, L. J., Martemyanov, K. A., Gloriam, D. E., & Babu, M. M. (2018) · Cell · doi:10.1016/j.cell.2017.11.033 · Cited by 616
Nikfarjam, A., Sarker, A., O’Connor, K., Ginn, R., & Gonzalez, G. (2015) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocu041 · Cited by 543
Al-Worafi, Y. M. (2020) · Drug Safety in Developing Countries · doi:10.1016/b978-0-12-819837-7.00005-4 · Cited by 390
Agbabiaka, T. B., Wider, B., Watson, L. K., & Goodman, C. (2017) · Drugs & Aging · doi:10.1007/s40266-017-0501-7 · Cited by 141
“ADRs could occur due to interactions between conventional drugs and HMPs, some of which may have serious consequences [15, 27–29].”
Metadata
- Authors
- Sultana, J., Cutroneo, P., & Trifirò, G.
- Venue
- Journal of Pharmacology and Pharmacotherapeutics
- Publisher
- SAGE Publications
- Published
- 2013-12
- Volume
- 4
- Issue
- 1_suppl
- Pages
- S73-S77
- ISSN
- 0976-500X (ISSN-L)
- 0976-5018
- OpenAlex
- W2073386434
- Cited by
- 528
- References
- 56
- FWCI
- 23.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.